Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

UroGen Pharma Ltd. Director's Dealing 2019

Jan 10, 2019

32312_dirs_2019-01-10_7735120d-6ee4-4f82-91c5-5c554a3cba68.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2019-01-01

Reporting Person: Nussbaum Ran (Director)

Holdings (Non-Derivative)

Security Shares Ownership
Ordinary Shares 968525 Indirect
Ordinary Shares 452162 Indirect

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (right to buy) $5.00 2021-07-27 Ordinary Shares (2211) Indirect
Stock Option (right to buy) $5.00 2022-09-01 Ordinary Shares (2211) Indirect
Stock Option (right to buy) $5.94 2022-12-27 Ordinary Shares (32723) Indirect
Stock Option (right to buy) $59.23 2028-06-04 Ordinary Shares (6817) Indirect
Stock Option (right to buy) $5.00 2021-07-27 Ordinary Shares (1030) Indirect
Stock Option (right to buy) $5.00 2022-09-01 Ordinary Shares (1030) Indirect
Stock Option (right to buy) $5.94 2022-12-27 Ordinary Shares (15276) Indirect
Stock Option (right to buy) $59.23 2028-06-04 Ordinary Shares (3183) Indirect

Footnotes

F1: The reportable securities are owned by Pontifax (Israel) III Limited Partnership ("Pontifax Israel") . The Reporting Person is a director of Pontifax Israel.

F2: The reportable securities are owned by Pontifax Cayman III Limited Partnership ("Pontifax Cayman") . The Reporting Person is a director of Pontifax Cayman.

F3: Fully vested.

F4: 33.33% of the shares underlying the stock option vested on each of December 27, 2016, December 27, 2017 and December 27, 2018.

F5: 25% of the shares underlying the stock option vested on each of September 4, 2018 and December 4, 2018 and the remaining shares will vest 25% on each of March 4, 2019 and June 4, 2019.